Robin Carhart-Harris, PhD, is the Ralph Metzner Distinguished Professor of Neurology, Psychiatry, and Behavioral Sciences at the University of California, San Francisco, where he founded and directs the Carhart-Harris Lab. He previously founded and led the world's first Centre for Psychedelic Research at Imperial College London.

A psychopharmacologist by training, with a PhD from the University of Bristol and an MA in Psychoanalysis from Brunel University, Robin has spent nearly two decades conducting pioneering neuroimaging studies with LSD, psilocybin, MDMA, and DMT. This research has fundamentally reshaped our scientific understanding of the psychedelic state. His clinical trials of psilocybin therapy, including a landmark study published in the New England Journal of Medicine, have demonstrated its potential for treating depression and other conditions long considered treatment-resistant.

Robin is best known for developing the concept of the "entropic brain" and for reframing mental illness not merely as chemical imbalance, but as a state of excessive mental rigidity, offering a new paradigm for how psychedelics can loosen entrenched patterns of thought and open pathways to healing. He is the author of How Psychedelics Work and has been named to Time's "100 Next" and Vox's "Future 50." His research has been featured in The New York Times, Nature, and The Guardian, among others.